YI Shiqin1, LI Yanshan2, MIAO Lixia2, SUN Yanfeng2, WANG Jun2, LIU Hongyan2, YANG Xinji2, and LIU Qiuling2
1. Xuzhou Medical College, Xuzhou 221002, China; 2. Department of Pediatrics, The General Hospital of Chinese People’s Armed Police Forces, Beijing 100039, China
Abstract：Objective To establish a retinoblastoma model and provide an animal model for the new treatment of RB. Methods Forty CD1 postnatal day 1 mice were randomly divided into 4 groups ( A,B, C, D), 10 in each. We set the right eye of each mouse as experiment group and the left as control. Different density of RB-Y9 cells(A 2.0×107/ml,B 3.0×107/ml,C 3.5×107/ml,D 4.0×107/ml, 4 μl/one) were injected into the vitreous cavity of right eyes, and the left eyes were injected with the same volume of cell culture medium. We closely monitored the tumor growth after injection and found the most appropriate density of the cells for the model construction. We used HE staining to analyze the tumor formation and histology and convinced that the tumor was RB. Results After the cell injection, we found no tumor formation in control group and most mice in the experiment group had tumors. Different density of injeced cells resulted in different rates of survival and tumor formation: the rate of tumor formation in the above 4 groups were 20%,80%,100% and 100% and the survival rates were100%,80%,80% and 50%. We regarded the C group (the density of the cells was 3.5×107/ml) as the best model for the experiment. HE staining of the tumor tissues implied that the structure of right eyes were severely destroyed and the cells had different size and were irregularly shaped: some were circular, oval and others were polygonal or irregular. The tumor cells had less cytoplasm and bigger nuclei when compared with normal controls. Cells with more than 1-2 nuclei can be frequently observed. Conclusions By injecting RB-Y79 cells in the vitreous cavity of neonatal mice can successfully develop the RB mouse model.
伊世芹,李彦珊,苗丽霞,孙岩峰,王军,刘红艳,杨新吉,刘秋玲. 视网膜母细胞瘤小鼠模型的建立[J]. 武警医学, 2014, 25(12): 1248-1251.
YI Shiqin, LI Yanshan, MIAO Lixia, SUN Yanfeng, WANG Jun, LIU Hongyan, YANG Xinji, and LIU Qiuling. Development of a new retinoblastoma mouse model. Med. J. Chin. Peop. Armed Poli. Forc., 2014, 25(12): 1248-1251.
Rygaard J, Povsen C O. Heterotransplantation of a human malignant tumour to "nude" mice [J]. Acta Pathol Microbiol Scand,1969, 77(4): 758-760.
[1]
Dimaras H, Kimani K, Dimba E A, et al. Retinoblastoma [J]. Lancet, 2012, 379(9844):1436-1446.
[2]
Leal-Leal C, Flores-Rojo M, Medina-Sanson A, et al. A multicentre report from the Mexican Retinoblastoma Group[J]. Br J Ophthalmol, 2004, 88(8): 1074-1077.
[6]
Gallie B L, Albert D M, Wong J J, et al. Invest Ophthalmol [J]. Vis Sci, 1977, 16(3): 256-259.
Chen D, Livne-bar I, Vanderluit J L, et al. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma [J]. Cancer cell, 2004,5(6): 539-551.
[3]
Broaddus E, Topham A, Singh A D. Incidence of retinoblastoma in the USA: 1975-2004[J]. Br J Ophthalmol, 2009, 93(1): 21-23.
[10]
MacPherson D, Sage J, Kim T, et al. Cell type-specific effects of Rb deletion in the murine retina [J]. Genes Dev, 2004,18(14): 1681-1694.
[4]
Shields C L, Shields J A. Diagnosis and management of retinoblastoma [J]. Cancer control, 2004,15(11):317-327.
[11]
Dyer M A, Bremner R. The search for the retinoblastoma cell of origin[J]. Nat Rev Cancer, 2005,5(2): 91-101.
[5]
Rygaard J, Povsen C O. Heterotransplantation of a human malignant tumour to "nude" mice [J]. Acta Pathol Microbiol Scand,1969, 77(4): 758-760.
[12]
Zhang J, SchweersB, Dyer M A. The first knockout mouse model of retinoblastoma[J]. Cell Cycle, 2004,3(7): 952-959 .
[6]
Gallie B L, Albert D M, Wong J J, et al. Invest Ophthalmol [J]. Vis Sci, 1977, 16(3): 256-259.
[13]
McFall R C, Sery T W, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma[J]. Cancer Res, 1977, 37(8): 1003-1010.
Dyer M A, Rodriguez-Galindo C, Wilson M W. Use of preclinical models to improve treatment of retinoblastoma [J]. PLoS Med, 2005,2(10): e332.
[9]
Chen D, Livne-bar I, Vanderluit J L, et al. Cell-specific effects of RB or RB/p107 loss on retinal development implicate an intrinsically death-resistant cell-of-origin in retinoblastoma [J]. Cancer cell, 2004,5(6): 539-551.
[10]
MacPherson D, Sage J, Kim T, et al. Cell type-specific effects of Rb deletion in the murine retina [J]. Genes Dev, 2004,18(14): 1681-1694.
[11]
Dyer M A, Bremner R. The search for the retinoblastoma cell of origin[J]. Nat Rev Cancer, 2005,5(2): 91-101.
[12]
Zhang J, SchweersB, Dyer M A. The first knockout mouse model of retinoblastoma[J]. Cell Cycle, 2004,3(7): 952-959 .
[13]
McFall R C, Sery T W, Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma[J]. Cancer Res, 1977, 37(8): 1003-1010.
[14]
Dyer M A, Rodriguez-Galindo C, Wilson M W. Use of preclinical models to improve treatment of retinoblastoma [J]. PLoS Med, 2005,2(10): e332.
2014, Vol. 25 
